Cingulate (CING)
Develops once-daily ADHD medicines using a multi-core timed-release platform.
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed.
US FDA declines to approve Cingulate's ADHD drug
Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder.
Cingulate Receives Complete Response Letter from FDA for CTx-1301
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter for its New Drug Application (“NDA”) for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance.
Why did Cingulate stock skyrocket today?
Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively safeguards the proprietary technology behind Cingulate's lead ADHD candidate – CTx-1301 – providing a massive boost to investor confidence as the company prepares for a transformative year.
Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price
Cingulate Inc. (NASDAQ:CING) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflect continued progress toward transforming CTx-1301 into a commercial ADHD franchise.
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate reported 2Q25 results that highlight continued progress toward the commercial launch of its lead ADHD asset, CTx-1301.
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026
Cingulate Provides Management Team Update
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J.
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)
Dallas, Texas--(Newsfile Corp. - June 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners initiates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate reported 1Q25 results that highlight continued progress toward the commercial launch of its lead ADHD asset, CTx-1301.